ATE394673T1 - Selbstanordnende moleküle - Google Patents

Selbstanordnende moleküle

Info

Publication number
ATE394673T1
ATE394673T1 AT02781023T AT02781023T ATE394673T1 AT E394673 T1 ATE394673 T1 AT E394673T1 AT 02781023 T AT02781023 T AT 02781023T AT 02781023 T AT02781023 T AT 02781023T AT E394673 T1 ATE394673 T1 AT E394673T1
Authority
AT
Austria
Prior art keywords
self
assembly
target
molecules
single domain
Prior art date
Application number
AT02781023T
Other languages
English (en)
Inventor
C Mackenzie
Jianbing Zhang
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE394673T1 publication Critical patent/ATE394673T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
AT02781023T 2001-11-30 2002-11-29 Selbstanordnende moleküle ATE394673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33409801P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE394673T1 true ATE394673T1 (de) 2008-05-15

Family

ID=23305560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781023T ATE394673T1 (de) 2001-11-30 2002-11-29 Selbstanordnende moleküle

Country Status (14)

Country Link
US (1) US7655412B2 (de)
EP (1) EP1456651B1 (de)
JP (1) JP4471656B2 (de)
CN (1) CN100335900C (de)
AT (1) ATE394673T1 (de)
AU (1) AU2002349228B2 (de)
BR (1) BR0214621A (de)
CA (1) CA2468583C (de)
DE (1) DE60226486D1 (de)
DK (1) DK1456651T3 (de)
ES (1) ES2306794T3 (de)
MX (1) MXPA04005134A (de)
NZ (1) NZ532838A (de)
WO (1) WO2003046560A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1523496B1 (de) 2002-07-18 2011-06-29 Merus B.V. Rekombinante Produktion von Antikörpermischungen
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP2711025A3 (de) * 2003-06-25 2014-09-10 Massachusetts Institute of Technology Selbstangeordnete Peptide mit Modifikationen und Verwendungsverfahren dafür
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
EP2267028A3 (de) * 2003-06-30 2011-07-27 Domantis Limited Dual-spezifischer Einzeldomäne-Antikörper (dAb) konjugiert an PEG
JP5618453B2 (ja) * 2003-11-28 2014-11-05 ナショナル リサーチ カウンシル オブ カナダ 抗癌抗体およびその使用
JP5912211B2 (ja) * 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
WO2007036021A1 (en) * 2005-09-27 2007-04-05 National Research Council Of Canada Blood-brain barrier epitopes and uses thereof
WO2008067591A1 (en) * 2006-12-04 2008-06-12 Innovative Purification Technologies Pty Ltd Protein particles
US8586315B2 (en) * 2007-05-30 2013-11-19 Innovative Purification Technologies Pty Ltd Fluorescent protein particles
EP2692736B1 (de) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-spezifische antikörper
US9327022B2 (en) 2008-10-14 2016-05-03 National Research Council Of Canada BSA-specific antibodies
JP2012505893A (ja) * 2008-10-14 2012-03-08 ダウ アグロサイエンシィズ エルエルシー 粘膜送達ペンタボディ複合体（ｍｄｐｃ）による粘膜免疫応答の誘導
EP2352766A4 (de) * 2008-11-26 2012-06-13 Ca Nat Research Council Mit einzeldomänen-antikörpern konjugierte und in nanoaggregate eingebettete kügelchen
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
US20100247529A1 (en) * 2009-03-20 2010-09-30 William Patterson Cooperative and dynamic assembly of affinity complexes
WO2011134060A1 (en) 2010-04-27 2011-11-03 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
PL2621955T3 (pl) 2010-10-01 2018-07-31 National Research Council Of Canada Przeciwciała anty-CEACAM6 i ich zastosowania
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
EA201391086A1 (ru) 2011-01-28 2014-01-30 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
SG10201607371UA (en) 2012-04-20 2016-10-28 Merus Nv Methods and means for the production of ig-like molecules
BR112015009306A2 (pt) 2012-10-24 2017-08-22 Nat Res Council Canada Anticorpos anti-campylobacter jejuni e usos dos mesmos
MX2016011561A (es) 2014-03-06 2017-04-13 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
AU2014385799B2 (en) 2014-03-06 2020-10-22 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
AU2014385801B2 (en) 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
CN104004093B (zh) * 2014-06-03 2017-01-18 大连理工大学 一种抗人甲状旁腺激素的纳米抗体及其筛选方法和应用
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
EP3307784B1 (de) 2015-06-10 2021-12-22 National Research Council of Canada Carboanhydrase-ix-spezifische antikörper und verwendungen davon
US10738115B2 (en) 2016-07-06 2020-08-11 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
WO2018109663A1 (en) 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
WO2018138681A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
CA3052058A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
US20210324011A1 (en) * 2018-10-25 2021-10-21 University Of Washington Self-assembling protein homo-polymers
CN114099701B (zh) * 2021-11-29 2023-11-10 华中科技大学同济医学院附属协和医院 一种自组装复合多肽及其制备方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
EP0923738A1 (de) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Verfahren und zubereitungen für die verwendung von apurinischen/apyrimidinischen endonukleasen
ATE394492T1 (de) * 1996-10-28 2008-05-15 Univ Lausanne Verfahren zur oligomerisation von peptiden
HUP0002760A3 (en) * 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
CA2313028A1 (en) * 1997-12-01 1999-06-10 Cfy Biomedicals, Inc. Multivalent recombinant antibodies for treating hrv infections
US6310043B1 (en) * 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
AU3219300A (en) * 1999-02-01 2000-08-18 Beth Israel Deaconess Medical Center Comp/tsp-1, comp/tsp-2 and other chimeric proteins
AU3798500A (en) * 1999-04-09 2000-11-14 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
CA2385172A1 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US20020041865A1 (en) * 2000-01-20 2002-04-11 Richard Austin Methods for treating tumors

Also Published As

Publication number Publication date
WO2003046560B1 (en) 2003-10-16
AU2002349228B2 (en) 2007-06-14
MXPA04005134A (es) 2004-08-11
EP1456651B1 (de) 2008-05-07
EP1456651A2 (de) 2004-09-15
CA2468583C (en) 2012-05-01
CN100335900C (zh) 2007-09-05
NZ532838A (en) 2008-05-30
DE60226486D1 (de) 2008-06-19
JP4471656B2 (ja) 2010-06-02
AU2002349228A1 (en) 2003-06-10
BR0214621A (pt) 2004-10-13
US7655412B2 (en) 2010-02-02
ES2306794T3 (es) 2008-11-16
WO2003046560A2 (en) 2003-06-05
CN1596371A (zh) 2005-03-16
JP2005510719A (ja) 2005-04-21
WO2003046560A3 (en) 2003-09-04
DK1456651T3 (da) 2008-09-01
US20060051292A1 (en) 2006-03-09
CA2468583A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
DK1456651T3 (da) Selvsamlende molekyler
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
DE602006013029D1 (de) Anti-egfr-antikörper
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MA33213B1 (fr) Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
EA200800812A1 (ru) Композиции антитела против cd3
WO2009088805A3 (en) Antibody targeting through a modular recognition domain
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
RS52775B (en) CD19 OPTIMIZED ANTIBODY
RS52036B (en) ANGIOPOETIN-2 ANTIBODIES AND ITS USES
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
NZ587230A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
NZ598770A (en) Monoclonal antibodies
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1456651

Country of ref document: EP